Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

USA – CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated approval guidance

The use of CRISPR-Cas9 gene editing technology has potential to transform the field of gene therapy through its simple and cost-effective delivery mechanism, said Peter Marks, director of the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), during a 23 April webinar sponsored by the Alliance for a Stronger FDA. He also addressed FDA’s forthcoming guidance on accelerated approval for gene therapies for treating rare diseases.

Marks also said that FDA needs to develop an agency-wide remote work policy. Currently, different centers within FDA have different policies in this area, he said. “We cannot have different centers in the agency have different human resource polices.” He added that “if we don’t have our medical product centers having similar policies this will lead to too much movement within the agency.”

Currently, FDA is in a “semi-stable state” allowing employees to either work remotely or on-site. He added that “my guess that the new normal will be a hybrid” model combining remote with onsite work.

More information on Regulatory Focus website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (4 octobre 2024). USA – CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated approval guidance. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/12f6t


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.